140 related articles for article (PubMed ID: 38291201)
21. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J
Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203
[TBL] [Abstract][Full Text] [Related]
23. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway.
Wei S; Zhang Y; Ma X; Yao Y; Zhou Q; Zhang W; Zhou C; Zhuang J
Sci Rep; 2023 Jul; 13(1):12351. PubMed ID: 37524857
[TBL] [Abstract][Full Text] [Related]
24. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.
Du L; Jing J; Wang Y; Xu X; Sun T; Shi Y; Wang W; Tian B; Han C; Zhao X; Chang H
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907854
[TBL] [Abstract][Full Text] [Related]
27. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
Xiao YS; Zeng D; Liang YK; Wu Y; Li MF; Qi YZ; Wei XL; Huang WH; Chen M; Zhang GJ
Cancer Lett; 2019 Jan; 440-441():156-167. PubMed ID: 30336197
[TBL] [Abstract][Full Text] [Related]
28. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
29. Ectopic expression of tumor suppressive miR-181c-5p downregulates oncogenic Notch signaling in MDA-MB-231 cells.
Shuaib M; Kumar S
Pathol Res Pract; 2024 Jan; 253():155017. PubMed ID: 38101160
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
[TBL] [Abstract][Full Text] [Related]
31. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
32. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
33. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.
Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C
Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771
[TBL] [Abstract][Full Text] [Related]
34. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
35. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
36. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.
Pamarthy S; Jaiswal MK; Kulshreshtha A; Katara GK; Gilman-Sachs A; Beaman KD
Oncotarget; 2015 Oct; 6(33):34206-20. PubMed ID: 26418877
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
38. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
39. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
Ozawa PMM; Alkhilaiwi F; Cavalli IJ; Malheiros D; de Souza Fonseca Ribeiro EM; Cavalli LR
Breast Cancer Res Treat; 2018 Dec; 172(3):713-723. PubMed ID: 30173296
[TBL] [Abstract][Full Text] [Related]
40. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
